Search research articles
Contact Us
Filters
Showing results (51-60 of 436) with videos related to
Page
of 44
Sort By:
Nature Reviews. Drug Discovery
|
May 18, 2013
The most transformative drugs of the past 25 years: a survey of physicians
Aaron S Kesselheim, Jerry Avorn
The New England Journal of Medicine
|
April 15, 2020
Drug Evaluation during the Covid-19 Pandemic
Benjamin N Rome, Jerry Avorn
JAMA
|
September 18, 2003
Internet marketing of herbal products
Charles A Morris, Jerry Avorn
Circulation
|
May 26, 2010
Funding for medical education: maintaining a healthy separation from industry
Jerry Avorn, Niteesh K Choudhry
JAMA
|
October 25, 2016
Approving a Problematic Muscular Dystrophy Drug: Implications for FDA Policy
Aaron S Kesselheim, Jerry Avorn
JAMA
|
February 7, 2017
Step Therapy-Clinical Algorithms, Legislation, and Optimal Prescribing
Michael A Fischer, Jerry Avorn
Health Affairs (Project Hope)
|
October 11, 2012
Academic detailing can play a key role in assessing and implementing comparative effectiveness research findings
Michael A Fischer, Jerry Avorn
Circulation
|
December 16, 2004
Comparing the costs, risks, and benefits of competing strategies for the primary prevention of venous thromboembolism
Jerry Avorn, Wolfgang C Winkelmayer
JAMA
|
January 26, 2006
Biomedical patents and the public's health: is there a role for eminent domain?
Aaron S Kesselheim, Jerry Avorn
Health Affairs (Project Hope)
|
May 9, 2007
Educating patients about their medications: the potential and limitations of written drug information
William H Shrank, Jerry Avorn
Page
of 44
Search research articles
Search
Showing results (51-60 of 436) with videos related to
Sort By:
Page
of 44
Nature Reviews. Drug Discovery
|
May 18, 2013
The most transformative drugs of the past 25 years: a survey of physicians
Aaron S Kesselheim, Jerry Avorn
The New England Journal of Medicine
|
April 15, 2020
Drug Evaluation during the Covid-19 Pandemic
Benjamin N Rome, Jerry Avorn
JAMA
|
September 18, 2003
Internet marketing of herbal products
Charles A Morris, Jerry Avorn
Circulation
|
May 26, 2010
Funding for medical education: maintaining a healthy separation from industry
Jerry Avorn, Niteesh K Choudhry
JAMA
|
October 25, 2016
Approving a Problematic Muscular Dystrophy Drug: Implications for FDA Policy
Aaron S Kesselheim, Jerry Avorn
JAMA
|
February 7, 2017
Step Therapy-Clinical Algorithms, Legislation, and Optimal Prescribing
Michael A Fischer, Jerry Avorn
Health Affairs (Project Hope)
|
October 11, 2012
Academic detailing can play a key role in assessing and implementing comparative effectiveness research findings
Michael A Fischer, Jerry Avorn
Circulation
|
December 16, 2004
Comparing the costs, risks, and benefits of competing strategies for the primary prevention of venous thromboembolism
Jerry Avorn, Wolfgang C Winkelmayer
JAMA
|
January 26, 2006
Biomedical patents and the public's health: is there a role for eminent domain?
Aaron S Kesselheim, Jerry Avorn
Health Affairs (Project Hope)
|
May 9, 2007
Educating patients about their medications: the potential and limitations of written drug information
William H Shrank, Jerry Avorn
Page
of 44